What is William Blair’s Forecast for IONS FY2028 Earnings?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) – William Blair dropped their FY2028 earnings per share estimates for shares of Ionis Pharmaceuticals in a note issued to investors on Friday, December 20th. William Blair analyst M. Minter now anticipates that the company will post earnings of $2.07 per share for the year, down from their prior estimate of $2.26. William Blair has a “Outperform” rating on the stock. The consensus estimate for Ionis Pharmaceuticals’ current full-year earnings is ($3.37) per share.

Other research analysts also recently issued reports about the stock. StockNews.com downgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, November 12th. Guggenheim cut their price target on Ionis Pharmaceuticals from $70.00 to $65.00 and set a “buy” rating for the company in a report on Wednesday, October 9th. Royal Bank of Canada reiterated an “outperform” rating and set a $70.00 price objective on shares of Ionis Pharmaceuticals in a research note on Thursday, September 26th. Needham & Company LLC restated a “buy” rating and issued a $60.00 target price on shares of Ionis Pharmaceuticals in a research note on Friday. Finally, JPMorgan Chase & Co. lifted their target price on Ionis Pharmaceuticals from $50.00 to $55.00 and gave the company a “neutral” rating in a report on Monday, August 26th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $60.65.

Ionis Pharmaceuticals Price Performance

IONS opened at $35.63 on Monday. The company has a market capitalization of $5.63 billion, a price-to-earnings ratio of -14.60 and a beta of 0.35. The company has a quick ratio of 8.82, a current ratio of 8.91 and a debt-to-equity ratio of 1.86. The firm has a 50-day moving average price of $37.38 and a 200-day moving average price of $42.27. Ionis Pharmaceuticals has a twelve month low of $33.33 and a twelve month high of $54.44.

Insider Transactions at Ionis Pharmaceuticals

In related news, EVP Eric Swayze sold 1,194 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $37.92, for a total value of $45,276.48. Following the completion of the sale, the executive vice president now owns 33,713 shares in the company, valued at $1,278,396.96. The trade was a 3.42 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Brett P. Monia sold 6,630 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $38.05, for a total value of $252,271.50. Following the completion of the sale, the chief executive officer now directly owns 167,393 shares of the company’s stock, valued at approximately $6,369,303.65. This represents a 3.81 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 7,877 shares of company stock valued at $299,578 in the last quarter. Insiders own 2.71% of the company’s stock.

Institutional Investors Weigh In On Ionis Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the business. Checchi Capital Advisers LLC bought a new position in shares of Ionis Pharmaceuticals during the 2nd quarter valued at $202,000. BLB&B Advisors LLC grew its stake in shares of Ionis Pharmaceuticals by 5.2% during the second quarter. BLB&B Advisors LLC now owns 153,750 shares of the company’s stock valued at $7,328,000 after buying an additional 7,650 shares during the last quarter. Peregrine Capital Management LLC increased its holdings in shares of Ionis Pharmaceuticals by 11.3% in the second quarter. Peregrine Capital Management LLC now owns 132,024 shares of the company’s stock worth $6,292,000 after buying an additional 13,426 shares during the period. International Assets Investment Management LLC lifted its stake in shares of Ionis Pharmaceuticals by 27.6% in the 2nd quarter. International Assets Investment Management LLC now owns 9,707 shares of the company’s stock valued at $463,000 after acquiring an additional 2,100 shares during the last quarter. Finally, Commonwealth Equity Services LLC boosted its holdings in Ionis Pharmaceuticals by 3.2% during the 2nd quarter. Commonwealth Equity Services LLC now owns 22,669 shares of the company’s stock valued at $1,080,000 after acquiring an additional 695 shares during the period. 93.86% of the stock is currently owned by institutional investors.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.